You are here:
rivaroxaban (Xarelto) DVT
following a full submission:
rivaroxaban (Xarelto®) is accepted for use within NHS Scotland.
Indication under review: treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.
Rivaroxaban has been shown to be non-inferior to standard anticoagulant therapy including a low molecular weight heparin in combination with a vitamin K antagonist for the treatment of proximal DVT and prevention of recurrence.
Experience with rivaroxaban in this indication for more than 12 months is limited therefore the cost-effectiveness of indefinite treatment has not been demonstrated.
|Drug Name:||rivaroxaban (Xarelto) DVT|
|SMC Drug ID:||755/12|
|Manufacturer:||Bayer plc/Bayer Schering Pharma|
|Indication:||For the treatment of DVT and prevention of recurrent DVT & pulmonary embolism following acute DVT in adults|
|Sub Category:||2.8 Anticoagulants and protamine|
|Submission Type:||Full submission|
|Date Advice Published:||13 February 2012|